Not too sure about a seasonal issue with Derm. This is only area of Mayne supporting the ridiculous S & M costs associated with our revenue. It has happened before and the bottom fell out when SRs doctored figures were bought to light I don’t know how but we have spent considerably more on acquiring and marketing Nextellis than the entire valuation of Mayne Pharma. If this product cannot increase market share without being continually rammed down Doctors and Patients throats maybe we should just slash our huge sales force. The dermatology products must have gained market share through their quality and value for money.
MYX Price at posting:
$4.18 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)